Please login to the form below

Not currently logged in
Email:
Password:

oral octreotide acetate

This page shows the latest oral octreotide acetate news and features for those working in and with pharma, biotech and healthcare.

Roche licenses Chiasma’s acromegaly drug in $595m deal

Roche licenses Chiasma’s acromegaly drug in $595m deal

The licensing deal - valued at up to $595m - is for Octreolin (oral octreotide acetate), a drug candidate which which is currently in phase III testing for acromegaly and also in development ... Our oral octreotide has the potential to improve the

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics